MTOR and cancer: Similarly, we have also preclinically identified an acquired resistance mutation in mTOR (mTOR S2035F) with continuous in vitro rapalog treatment and demonstrated that cancer cells with this mutation are resistant to everolimus but are still sensitive to mTOR catalytic inhibitor TAK228 in vitro and in vivo37.